| William H. Leschey, Phd, P.a. | |
|
107 Delano Park Cape Elizabeth ME 04107-1934 | |
| (207) 650-9424 | |
| Not Available |
| Full Name | William H. Leschey, Phd, P.a. |
|---|---|
| Speciality | Psychologist |
| Location | 107 Delano Park, Cape Elizabeth, Maine |
| Authorized Official Name and Position | William H Leschey (OWNER) |
| Authorized Official Contact | 2076509424 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| William H. Leschey, Phd, P.a. 107 Delano Park Cape Elizabeth ME 04107-1934 Ph: (207) 650-9424 | William H. Leschey, Phd, P.a. 107 Delano Park Cape Elizabeth ME 04107-1934 Ph: (207) 650-9424 |
| NPI Number | 1568131530 |
|---|---|
| Provider Enumeration Date | 09/12/2021 |
| Last Update Date | 09/12/2021 |
| Certification Date | 09/12/2021 |
| Medicare PECOS PAC ID | 9638569569 |
|---|---|
| Medicare Enrollment ID | O20211208000005 |
News Archive
New research shows that sewage contains a source of energy that can be harvested by using hungry bacteria.
Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on its proprietary macrocyclic chemistry technology, and Haplogen GmbH, a biotechnology company developing anti-infective drugs, today announced the signing of a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas.
Gilead Sciences, Inc. today announced that the company has signed a definitive agreement under which Gilead will purchase a clinical biologics manufacturing facility and certain process development assets located in Oceanside, California from Genentech, a member of the Roche Group.
A vaccine that protects against a wide variety of influenza viruses (a so-called universal flu vaccine) is a critical public health goal given the significant rates of illness and death caused by seasonal influenza and the potentially devastating effects of a pandemic influenza strain.
The future success of Alzheimer's prevention research could depend on the ability of researchers from different clinical trials to build collaborative relationships that facilitate the sharing of information, resources and expertise that may speed the discovery of new preventive treatments, according to leading Alzheimer's researchers who published a Perspectives article, "CAP-advancing the evaluation of preclinical Alzheimer disease treatments," online today in Nature Reviews Neurology.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568131530 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | (* (Not Available)) | Primary |
| Provider Name | William H Leschey Iii |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1235192477 PECOS PAC ID: 4981799913 Enrollment ID: I20071004000731 |
News Archive
New research shows that sewage contains a source of energy that can be harvested by using hungry bacteria.
Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on its proprietary macrocyclic chemistry technology, and Haplogen GmbH, a biotechnology company developing anti-infective drugs, today announced the signing of a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas.
Gilead Sciences, Inc. today announced that the company has signed a definitive agreement under which Gilead will purchase a clinical biologics manufacturing facility and certain process development assets located in Oceanside, California from Genentech, a member of the Roche Group.
A vaccine that protects against a wide variety of influenza viruses (a so-called universal flu vaccine) is a critical public health goal given the significant rates of illness and death caused by seasonal influenza and the potentially devastating effects of a pandemic influenza strain.
The future success of Alzheimer's prevention research could depend on the ability of researchers from different clinical trials to build collaborative relationships that facilitate the sharing of information, resources and expertise that may speed the discovery of new preventive treatments, according to leading Alzheimer's researchers who published a Perspectives article, "CAP-advancing the evaluation of preclinical Alzheimer disease treatments," online today in Nature Reviews Neurology.
› Verified 7 days ago
News Archive
New research shows that sewage contains a source of energy that can be harvested by using hungry bacteria.
Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on its proprietary macrocyclic chemistry technology, and Haplogen GmbH, a biotechnology company developing anti-infective drugs, today announced the signing of a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas.
Gilead Sciences, Inc. today announced that the company has signed a definitive agreement under which Gilead will purchase a clinical biologics manufacturing facility and certain process development assets located in Oceanside, California from Genentech, a member of the Roche Group.
A vaccine that protects against a wide variety of influenza viruses (a so-called universal flu vaccine) is a critical public health goal given the significant rates of illness and death caused by seasonal influenza and the potentially devastating effects of a pandemic influenza strain.
The future success of Alzheimer's prevention research could depend on the ability of researchers from different clinical trials to build collaborative relationships that facilitate the sharing of information, resources and expertise that may speed the discovery of new preventive treatments, according to leading Alzheimer's researchers who published a Perspectives article, "CAP-advancing the evaluation of preclinical Alzheimer disease treatments," online today in Nature Reviews Neurology.
› Verified 7 days ago
Cape Counseling Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2 Manor Way, Cape Elizabeth, ME 04107 Phone: 207-233-9303 | |
East Coast Wellness Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 553 Shore Rd Ste 2, Cape Elizabeth, ME 04107 Phone: 207-400-5876 | |
Kerry Bennett, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 541 Ocean House Rd, Cape Elizabeth, ME 04107 Phone: 206-930-6435 | |
Maine Medical Partners Internal Medicine Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 155 Spurwink Ave, Cape Elizabeth, ME 04107 Phone: 207-767-2174 Fax: 207-767-1384 | |
Kathryn Mitchell Counseling, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 40 Fowler Rd, Cape Elizabeth, ME 04107 Phone: 603-660-2369 | |
Julia L Orr Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 20 Cheverus Rd, Cape Elizabeth, ME 04107 Phone: 207-329-6156 |